Verseon Corporation Special Shareholder Meeting & Change of Directors (6403R)
September 25 2017 - 1:01AM
UK Regulatory
TIDMVSN
RNS Number : 6403R
Verseon Corporation
25 September 2017
Press release September 25, 2017
Verseon Corporation
("Verseon" or the "Company")
Announcement of Special Shareholder Meeting and Change of
Directors
FREMONT, Calif.-Verseon Corporation (AIM:VSN), a
technology-based pharmaceutical company, is pleased to announce
that Dr. Robert Karr has accepted the nomination for a position on
the Verseon Board of Directors. His appointment is subject to
approval at a Special Shareholder Meeting ("Special Meeting") for
the election of a Class II Director, which will be held at 7100
Stevenson Blvd, Fremont, CA 94538 on October 19, 2017 at 2 p.m.
local time, and the completion of customary UK regulatory
requirements. Alastair Cade, a Class II Non-Executive Director of
the Company, has stepped down from his position on the Board of
Directors with immediate effect.
Dr. Robert Karr, the former Senior Vice President of R&D
Strategy at Pfizer, is currently the Chief Scientific Officer at
Tioma, an immuno-oncology company developing antibody treatments
for solid and hematologic cancers. During his extensive career in
the pharmaceutical industry, Dr. Karr has held various senior
executive positions at Idera Pharmaceuticals, Pfizer, and
Warner-Lambert. Prior to his career in industry, Dr. Karr completed
his internship, residency, and fellowship at Washington University
School of Medicine and held a faculty position at University of
Iowa College of Medicine.
Copies of the following Special Meeting documents will be
available to view and download between September 25 and October 19,
2017 from the Company's website at:
http://www.verseon.com/investor-notices/ssm2017-10-19:
-- Notice of Special Shareholder Meeting
-- Special Shareholder Meeting Proxy Information Statement
A further update regarding the appointment of Dr. Karr will be
provided on or around October 19, 2017.
- Ends -
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUCGBUPMPGC
(END) Dow Jones Newswires
September 25, 2017 02:01 ET (06:01 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024